



Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Regd Off: 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh – 452 011. Phone : +91 9884624100

Date: 06th May 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers
21st Floor, Dalal Street
Mumbai – 400001

BSE Scrip Code: 524322

Sub: Outcome of Board Meeting held on 06th May 2026, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e 06th May 2026 have considered and approved the following items:

1. Pharmaceutical Manufacturing & Marketing Expansion:

The Board approved the expansion of the Company's pharmaceutical manufacturing and marketing business through the launch of the Company's own generic branded formulations.

The expansion shall be executed in phases through strategic channel partners arranged by the Company in association with "Mr. Franchise", an external agency. Phase 1 shall focus on strengthening the Company's presence across South India, followed by expansion into other regions in subsequent phases.

The Board further authorized Mr. Nanjappan Aravind, Managing Director of the Company, to execute necessary agreements with channel partners, subject to completion of due diligence procedures, and to initiate project implementation immediately.

This initiative is expected to strengthen the Company's presence in high-growth therapeutic markets and improve access to affordable healthcare solutions.



Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Regd Off: 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh – 452 011. Phone : +91 9884624100

2. Defence & AI Integration:

The Board considered and approved the Company's proposed entry into defence manufacturing opportunities leveraging Artificial Intelligence (AI).

In this regard, the Company shall initiate the regulatory approval process with the Directorate General of Foreign Trade (DGFT) for obtaining the SCOMET License.

Further, the Board approved the establishment of a dedicated AI & Defence Technology Research & Development facility at Cactus TECCI Park, Chennai. The proposed facility shall serve as a hub for innovation in AI-driven defence technologies, positioning the Company as a contributor to national security and advanced manufacturing capabilities.

3. Postal Ballot & Revised cut-off dates:

Due to administrative reasons and technical difficulties, the company was unable to dispatch the postal ballot. After due consideration, the Board has duly approved the revision of the postal ballot notice, cut-off date, book closure period, e-voting schedule and the calendar of events for the postal ballot.

The revised Cut-off date for determination of shareholders who will be eligible for e-voting and receiving Postal Ballot Notice through emails would be Friday 08th May 2026 and Book closure dates would be from Tuesday, 12th May 2026 to Wednesday, 10th June 2026 both days inclusive.

The E-voting Facility will start from Tuesday, 12th May 2026 at 09:00 AM and end on Wednesday, 10th June 2026 at 05:00 PM (both days inclusive) and accordingly the revised the calendar of events for the proposed Postal Ballot process is attached as **Annexure - A**.

The Notice of Postal Ballot will be sent to the Members and the same shall be filed with the Stock Exchanges in due course.



Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Regd Off: 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh – 452 011. Phone : +91 9884624100

4. Any other business:

Strategic Appointment:

The Board approved the appointment of Mr. Alagiamanavalan as an Independent Consultant for domestic and international defence projects.

The meeting of the Board of Directors of the Company commenced at 05.00 p.m. (IST) and concluded at 06:30 p.m. (IST).

Kindly take the aforesaid information on record and oblige.

Thanking you,

Yours sincerely,

For Kabra Drugs Limited

Kuniamuthur Nanjappan Anand

Director

DIN: 03230186



Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Regd Off: 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh – 452 011. Phone : +91 9884624100

Annexure-A

Revised Calendar of Events for the Proposed Postal Ballot Process

| Sl. No | Particulars | Date |
|--------|--|---|
| 1. | Date on which consent is given by Scrutinizer | 10 th April 2026 |
| 2. | Date of Board Meeting authorizing Directors or Company Secretary to be responsible for the entire process | 21 st April 2026 |
| 3. | Date of appointment of the scrutinizer | 21 st April 2026 |
| 4. | Cut-off date for Sending Postal Ballot Notice to Shareholders and determining list of Members for E-voting | 08 th May 2026 |
| 5. | Date of completion of dispatch of Postal Ballot through electronic mode only | 11 th May 2026 |
| 6. | Date of publishing advertisement in Newspaper | 12 th May 2026 |
| 7. | E- Voting Start date | 12 th May 2026 |
| 8. | E- Voting Start Time | 9.00 A.M IST |
| 9. | E- Voting End date | 10 th June 2026 |
| 10. | E -Voting End Time | 5.00 P.M IST |
| 11. | Date on which Resolution shall be deemed to be passed | 10 th June 2026 |
| 12. | Date of submission of report by the Scrutinizer | On or before 12 th June 2026 |
| 13. | Date of declaration of the result by the Chairman | On or before 12 th June 2026 |
| 14. | Contact Person of the company (Co-Ordinator of E-voting) | Mr. K. N. Anand |
| 15. | Designation | Director |
| 16. | Contact No. | 9884624100 |
| 17. | Email address | kabradrugs@gmail.com |